Novel anti-obesity drugs

Bibliography

• LEIBEL RL, ROSENBAUM M, HIRSCH J: Changes in energy expenditure resulting from altered body weight. N. Engl. J. Med. (1995) 332:621–628.
   PubMed Web of Science ®Google Scholar
• ••Provides evidence for homeostatic regulation of bodyweight.
   Google Scholar
• INUI A: Feeding and body-weight regulation by hypothalamic neuropeptides-mediation of the actions of leptin. Trends Neurosci. (1999) 22(2):62–67.
   PubMed Web of Science ®Google Scholar
• LEVINE JA, EBERHARDT NL, JENSEN MD: Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science (1999) 283:212–214.
   PubMed Web of Science ®Google Scholar
• ••See reference 1 for annotation.
   Google Scholar
• ZHANG Y, PROENCA R, MAFFEI M et al.: Positional cloning of the mouse obese gene and its human homologue. Nature (1994) 372:425–432.
   PubMed Web of Science ®Google Scholar
• •Describes the discovery of leptin.
   Google Scholar
• PELLEYMOUNTER MA, CULLEN MJ, BAKER MB et al.: Effects of the obese gene product on body weight regulation in ob/ob mice. Science (1 9 9 5) 269(5223):540–543.
   Google Scholar
• CARO JF, KOLACZYNSKI JW, NYCE MR et al.: Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet (1996) 348(9020:159–161.
   PubMedGoogle Scholar
• •Discusses a mechanism for leptin resistance.
   Google Scholar
• ARCH JR, STOCK MJ, TRAYHURN P: Leptin resistance in obese humans: does it exist and what does it mean? Int. J. Obes. Relat. Metab. Disord. (1998) 22(12):1159–1163.
   PubMed Web of Science ®Google Scholar
• CHEN H, CHARLAT O, TARTAGLIA LA et al.:Evidence that the diabetes gene encodes the leptin receptor: identifi-cation of a mutation in the leptin receptor gene in db/db mice. Cell (1996) 84(3):491–495.
   PubMed Web of Science ®Google Scholar
• CHUA SC JR, CHUNG WK, WU-PENG XS et al.: Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science (1996) 271(5250:994–996.
   PubMedGoogle Scholar
• CONSIDINE RV, CONSIDINE EL, WILLIAMS CJ, HYDE TM, CARO JF: The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations. Diabetes (1996) 45(7):992–994.
   PubMed Web of Science ®Google Scholar
• GOTODA T, MANNING BS, GOLDSTONE AP et al.: Leptinreceptor gene variation and obesity: lack of associa-tion in a white British male population. Hum Mol Genet (1997) 6(6):869–876.
   PubMed Web of Science ®Google Scholar
• CLEMENT K, VAISSE C, LAHLOU N et al.: A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature (1998) 392(6674):398–401.
   PubMed Web of Science ®Google Scholar
• •Reports the discovery of human leptin receptor mutation causing severe obesity.
   Google Scholar
• HINNEY A, SHMIDT A, NOTTEBOM K et al.: Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. J. Clin. Endocrinol. Metab. (1999) 84:1483–1486.
   PubMed Web of Science ®Google Scholar
• VAISSE C, CLEMENT K, GUY-GRAND B, FROGUEL P: A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nature Genet. (1998) 20(2):113–114.
   PubMed Web of Science ®Google Scholar
• YE0 GS, FAROOQI IS, AMINIAN S, HALSALL DJ, STANHOPE RG, O'RAHILLY S: A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nature Genet. (1998) 20(2):111–112.
   PubMed Web of Science ®Google Scholar
• •Reports the discovery of melanocortin 4 receptor mutation causing severe obesity.
   Google Scholar
• CHEN D, GARG A: Monogenic disorders of obesity and body fat distribution. J. Lipid. Res. (1 9 9 9) 40(10):1735–1746.
   Google Scholar
• GELDSZUS R, MAYR B, HORN R, GEISTHOVEL F, VON ZUR MUHLEN A, BRABANT G: Serum leptin and weight reduction in female obesity. Eur. J. Endocrinol. (1996) 135(6):659–662.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates a reduction of circulating leptin followingweight loss.
   Google Scholar
• KEIM NL, STERN JS, HAVEL PJ: Relation between circulating leptin concentrations and appetite during a prolonged, moderate energy deficit in women. Am.J. Clin. Nutr. (1998) 68(4):794–801.
   PubMed Web of Science ®Google Scholar
• •See reference 17 for annotation.
   Google Scholar
• WISSE BE, CAMPFIELD LA, MARLISS EB, MORAIS JA, TENENBAUM R, GOUGEON R: Effect of prolonged moderate and severe energy restriction and refeeding on plasma leptin concentrations in obese women. Am. J. Clin. Nutr. (1999) 70(3):321–330.
   PubMed Web of Science ®Google Scholar
• •See reference 17 for annotation.
   Google Scholar
• CONNOLLY HM, CRARY JM, MCGOON MD et al.: Valvular heart disease associated with fenfluramine-phenterrnine. N Engl. J. Med. (1997) 337:581–588.
   PubMed Web of Science ®Google Scholar
• •Describes cardiac valvular lesions with serotinergic agents.
   Google Scholar
• GRAHAM DJ, GREEN L: Further cases of valvular heart disease associated with fenflurarnine-phentermine. N Engl. J. Med. (1997) 337:635.
   PubMed Web of Science ®Google Scholar
• CANNISTRA L: Valvular heart disease associated with dexfenflurarnine. N Engl. J. Med. (1997) 337:636.
   PubMed Web of Science ®Google Scholar
• MORITA T, MEHANDALE HM: Effects of chlorphenter-mine and phentermine on the pulmonary disposition of 5-hydroxytryptarnine in the rat in vivo. Am. Rev. Respir. Dis. (1983) 127:747–750.
   PubMed Web of Science ®Google Scholar
• MARK EJ, PATALAS ED, CHANG HT et al.: Fatal pulmonary hypertension associated with short-term use of fenflurarnine and phentermine. N. Engl. J. Med. (1997) 337:602–606.
   PubMed Web of Science ®Google Scholar
• ABENHAIM L, MORIDE Y, BRENOT F et al.: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med. (1996) 335:609–616.
   PubMed Web of Science ®Google Scholar
• •Describes pulmonary hypertension with serotinergic agents.
   Google Scholar
• WARD AS, COMER SD, HANEY M et al.: Fluoxetine-maintained obese humans: effect on food intake and body weight. Physiol. Behav. (1999) 66:815–821.
   PubMed Web of Science ®Google Scholar
• CAMPBELL CJ, BHALLA IP, STEEL JM, DUNCAN LJ: A controlled trial of phentermine in obese diabetic patients. Practitioner (1977) 218:851–855.
   PubMedGoogle Scholar
• SJOSTROM L, RISSANEN A, ANDERSEN T et al.: Random-ised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (1998) 352:167–172.
   PubMed Web of Science ®Google Scholar
• •Results of a clinical trial of orlistat.
   Google Scholar
• DAVIDSON MH, HAUPTMAN J, DIGIROLAMO M et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA (1999) 281:235–242.
   PubMed Web of Science ®Google Scholar
• HILL JO, HAUPTMAN J, ANDERSON JW et al.: Orlistat, a lipase inhibitor, for weight maintenance after conven-tional dieting: a 1-y study. Am. J. Clin. Nutr. (1999) 69(6):1108–1116.
   PubMed Web of Science ®Google Scholar
• HOLLANDER PA, ELBEIN SC, HIRSCH TB et al.: Role oforlistat in the treatment of obese patients with Type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care (1998) 21:1288–1294.
   Google Scholar
• JACKSON HC, NEEDHAM AM, HUTCHINS 41 et al.: Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br. J. Pharmacol. (1997) 121:1758–1762.
   Google Scholar
• HANSEN DL, TOUBRO S, STOCK MJ, MACDONALD IA, ASTRUP A: Thermogenic effects of sibutramine in humans. Am. J. Clin. Nutr. (1998) 68:1180–1186.
   PubMed Web of Science ®Google Scholar
• DANFORTH JR E: Sibutramine and thermogenesis in humans. Int. J. Obes. Relat. Metab. Disord. (1999) 23(10):1007–1008.
   PubMed Web of Science ®Google Scholar
• BRAY GA, BLACKBURN GL, FERGUSON JM et al.: Sibutra-mine produces dose-related weight loss. Obes. Res. (1999) 7:189–198.
   PubMedGoogle Scholar
• •Results of a clinical trial of sibutramine.
   Google Scholar
• HANOTIN C, THOMAS F, JONES SP, LEUTENEGGER E, DROUIN P: Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int. J. Obes. Relat. Metab. Disord. (1998) 22:32–38.
   PubMed Web of Science ®Google Scholar
• •Results of a clinical trial of leptin.
   Google Scholar
• LEAN ME: Sibutramine - a review of clinical efficacy. Int. J. Obes. Relat. Metab. Disord. (1997) 21\(Suppl. 1):S30–S36.
   Google Scholar
• GUNDLAH C, MARTIN KF, HEAL DJ, AUERBACH SB: In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J. Pharmacol. Exp. Ther. (1997) 283(2):581–591.
   PubMed Web of Science ®Google Scholar
• FAROOQI IS, JEBB SA, LANGMACK G et al.: Effects ofrecombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. (1999) 341:879–884.
   PubMed Web of Science ®Google Scholar
• HEYMSFIELD SB, GREENBERG AS, FUJIOKA K et al.: Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JANIA (1999) 282(16):1568–1575.
   PubMed Web of Science ®Google Scholar
• CHANCE WT, BALASUBRAMANIAM A, ZHANG FS, WIMALAWANSA SJ, FISCHER JE: Anorexia following the intrahypothalamic administration of amylin. Brain. Res. (1991) 539:352–354.
   PubMed Web of Science ®Google Scholar
• MORLEY JE, FLOOD JF: Amylin decreases food intake in mice. Peptides (1991) 12:865–869.
   PubMed Web of Science ®Google Scholar
• MORLEY JE, FLOOD JF, HOROWITZ M, MORLEY PM, WALTER MJ: Modulation of food intake by peripherally administered amylin. Am. J. Physiol. (1994) 267:R178–R184.
   PubMed Web of Science ®Google Scholar
• BHAVSAR S, WATKINS J, YOUNG A: Synergy between amylin and cholecystokinin for inhibition of food intake in mice. Physiol. Behav. (1998) 64:557–561.
   PubMed Web of Science ®Google Scholar
• ARNELO U, PERMERT J, ADRIAN TE, LARSSON J, WESTER-MARK P, REIDELBERGER RD: Chronic infusion of islet amyloid polypeptide causes anorexia in rats. Am. J. Physiol. (1996) 271:R1654–R1659.
   PubMed Web of Science ®Google Scholar
• MARSH DJ, HOLLOPETER G, HUSZAR D et al.: Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nature Genet. (1999) 21(1):119–122.
   PubMed Web of Science ®Google Scholar
• PHILLIPS MS, LIU Q, HAMMOND HA et al.: Leptinreceptor missense mutation in the fatty Zucker rat. Nature Genet (1996) 13(1):18–19.
   PubMed Web of Science ®Google Scholar
• YAMASHITA T, MURAKAMI T, IIDA M, KUWAJIMA M, SHIMA K: Leptin receptor of Zucker fatty rat performs reduced signal transduction. Diabetes (1997) 46(6):1077–1080.
   PubMed Web of Science ®Google Scholar
• SCHIOTH HB, MUCENIECE R, WIKBERG JE: Characteriza-tion of the binding of MSH-B, HB-228, GHRP-6 and 153N-6 to the human melanocortin receptor subtypes. Neuropeptides (1997) 31:565–571.
   PubMed Web of Science ®Google Scholar
• BEDNAREK MA, MACNEIL T, KALYANI RN et al.: Analogs of MTh, lactam derivatives of alpha-melanotropin, modified at the N-terminus and their selectivity at human melanocortin receptors 3, 4 and 5. Biochem. Biophys. Res. Commun. (1999) 261(1):209–213.
   PubMed Web of Science ®Google Scholar
• MURPHY B, NUNES CN, RONAN JJ et al.: Melanocortin mediated inhibition of feeding behavior in rats. Neuropeptides (1998) 32(6):491–497.
   PubMed Web of Science ®Google Scholar
• FAN W, BOSTON BA, KESTERSON RA et al.: Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature (1997) 385:165–168.
   PubMed Web of Science ®Google Scholar
• PAEZ X, MYERS RD: Insatiable feeding evoked in rats by recurrent perfusion of neuropeptide Y in the hypothalamus. Peptides (1991) 12(3):609–616
   PubMed Web of Science ®Google Scholar
• SAINSBURY A, CUSIN I, ROHNER-JEANRENAUD F, JEANRENAUD B: Adrenalectomy prevents the obesity syndrome produced by chronic central neuropeptide Y infusion in normal rats. Diabetes (1997) 46:209–214.
   PubMed Web of Science ®Google Scholar
• KANATANI A, ISHIHARA A, ASAHI S, TANAKA T, OZAKI S,IHARA M: Potent neuropeptide Y Y1 receptor antago-nist, 1229U91: blockade of neuropeptide Y-induced and physiological food intake. Endocrinology (1996) 137:3177–3182.
   PubMed Web of Science ®Google Scholar
• MATTHEWS JE, JANSEN M, LYERLY D et al.: Pharma-cological characterization and selectivity of the NPY antagonist GR231118 (1229U91) for different NPY receptors. Regul. Pept. (1997) 72:113–119.
   PubMed Web of Science ®Google Scholar
• ISHIHARA A, TANAKA T, KANATANI A, FUKAMI T, IHARA M, FUKURODA T: A potent neuropeptide Y antagonist, 1229U91, suppressed spontaneous food intake in Zucker fatty rats. Am.J. Physiol. (1998) 274:R1500–R1504.
   PubMed Web of Science ®Google Scholar
• WIDDOWSON PS, HENDERSON L, PICKAVANCE L et al.: Hypothalamic NPY status during positive energy balance and the effects of the NPY antagonist, BW 1229U91, on the consumption of highly palaTable energy-rich diet. Peptides (1999) 20:367–372.
   PubMed Web of Science ®Google Scholar
• DOODS HN, WIELAND HA, ENGEL W et al.: BIBP 3226, the first selective neuropeptide Y1 receptor antago-nist: a review of its pharmacological properties. Regul. Pept. (1996) 27:71–77.
   Google Scholar
• KASK A, RAGO L, HARRO J: Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Yl-selective antagonist BIBP3226. Br. J. Pharmacol. (1998) 124:1507–1515.
   PubMed Web of Science ®Google Scholar
• MORGAN DG, SMALL CJ, ABUSNANA S et al.: The NPY Y1 receptor antagonist BIBP 3226 blocks NPY induced feeding via a non-specific mechanism. Regul. Pept. (1998) 75–76:377–382.
   Google Scholar
• SERRADEIL-LE GAL C, VALETTE G, ROUBY PE: SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FESS Lett.(1995)362(2):192–196.
   PubMed Web of Science ®Google Scholar
• ERICKSON JC, CLEGG KE, PALMITER RD: Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature (1996) 381:415–421.
   PubMed Web of Science ®Google Scholar
• GAUTHIER C, TAVERNIER G, CHARPENTIER F, LANGIN D, LE MAREC H: Functional beta3-adrenoreceptor in the human heart. J. Clin. Invest. (1996) 98(4:556–562.
   PubMedGoogle Scholar
• CHAMBERALIN PD, JENNINGS KH, PAUL F et al.: The tissue distribution of the human beta3-adrenoreceptor studied using a monoclonal antibody: direct evidence if the beta3-adrenoreceptor in human adipose tissue, atrium and skeletal muscle. Int. J. Obes. Relat. Metab. Disord. (1999) 23(10):1057–1065.
   PubMed Web of Science ®Google Scholar
• WEYER C, GAUTIER JF, DANFORTH E, Jr.: Developmentof beta 3-adrenoceptor agonists for the treatment of obesity and diabetes-an update. Diabetes Metab. (1999) 25(1):11–21.
   Google Scholar
• CONNACHER AA, JUNG RT, MITCHELL PE: Weight loss in obese subjects on a restricted diet given BRL 26830A, a new atypical beta adrenoceptor agonist. BMJ (1988) 296:1217–1220.
   PubMed Web of Science ®Google Scholar
• CONNACHER AA, LAME M, POWERS N, ELTON RA, WALSH EG, JUNG RT: Tremor and the anti-obesity drug BRL 26830A. Br. J. Qin. Pharmacol. (1990) 30:613–615.
   Web of Science ®Google Scholar
• JEQUIER E, MUNGER R, FELBER JP: Thermogenic effects of various beta-adrenoceptor agonists in humans: their potential usefulness in the treatment of obesity. Am. J. Clin. Nutr. (1992) 55\(Suppl. 1):2495–2515.
   Google Scholar
• HAESLER E, GOLAY A, GUZELHAN C et al.: Effect of a novel beta-adrenoceptor agonist (Ro 40-2148) on resting energy expenditure in obese women. Int. J. Obes. Relat. Metab. Disord. (1994) 18(5):313–322.
   PubMed Web of Science ®Google Scholar
• WEYER C, TATARANNI PA, SNITKER S et al.: Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes (1998) 47(10):1555–1561.
   PubMed Web of Science ®Google Scholar
• SIEGEL EG, SCHARF G, GALLWITZ B et al.: Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets. Eur. J. Clin. Invest. (1999) 29(7):610–614.
   PubMed Web of Science ®Google Scholar
• WEST DB, FEY D, WOODS SC: Cholecystokinin persis-tently suppresse meal size but not food intake in free-feeding rats. Am. J. Physiol (1984) 246:R776–R787.
   PubMedGoogle Scholar